表紙
市場調査レポート

化学療法誘発性末梢神経障害:パイプライン製品の分析

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 245976
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
化学療法誘発性末梢神経障害:パイプライン製品の分析 Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016
出版日: 2016年03月22日 ページ情報: 英文 91 Pages
概要

化学療法誘発性末梢神経障害 (CIPN) は、がん治療の副作用の一種です。主な症状として、疼痛や灼熱感、刺すような痛み、便秘、筋力低下、血圧の変動、バランス感覚の喪失などが挙げられます。主なリスク要因には、治療の長期化や、以前から罹患している神経症、化学療法用の医薬品の種類などがあります。

当レポートでは、世界各国での化学療法誘発性末梢神経障害治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

化学療法誘発性末梢神経障害の概要

治療薬の開発

  • 化学療法誘発性末梢神経障害向けパイプライン製品:概要
  • 化学療法誘発性末梢神経障害向けパイプライン製品:比較分析

各企業で開発中の化学療法誘発性末梢神経障害治療薬

大学/研究機関で研究中の化学療法誘発性末梢神経障害治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

化学療法誘発性末梢神経障害治療薬:開発中の製品の一覧 (企業別)

化学療法誘発性末梢神経障害治療薬:研究中の製品の一覧 (大学/研究機関別)

化学療法誘発性末梢神経障害治療薬の開発に従事している企業

  • DARA BioSciences, Inc.
  • DermaXon, LLC
  • エーザイ
  • Immune Pharmaceuticals Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • MAKScientific, LLC
  • Mertiva AB
  • Panacea Pharmaceuticals, Inc.
  • PharmatrophiX, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Spinifex Pharmaceuticals Pty Limited
  • Virobay Inc.

化学療法誘発性末梢神経障害:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • アミトリプチリン+塩酸ケタミン
    • 製品概要
    • 機能メカニズム
    • 研究開発 (R&D) の進展状況
  • AL-309
  • AM-1710
  • 疼痛向け治療薬
  • DX-0332
  • E-2072
  • E-52862
  • EMA-401
  • 化学療法誘発性末梢神経障害向け遺伝子療法
  • ketoprofen
  • KRN-5500
  • LM11A-31
  • PAN-811
  • PGN-703
  • 末梢神経障害・ALS (筋萎縮性側索硬化症) 向け小分子
  • SPI-205
  • VBY-036

化学療法誘発性末梢神経障害治療薬:パイプライン製品の最新動向

化学療法誘発性末梢神経障害治療薬:開発が休止状態の製品

化学療法誘発性末梢神経障害治療薬:開発が中止された製品

化学療法誘発性末梢神経障害関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース (全6件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7733IDB

Summary

Global Markets Direct's, 'Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016', provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
  • The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects
  • The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Peripheral Neuropathy Overview
  • Therapeutics Development
    • Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview
    • Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies
  • Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes
  • Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
    • Achelios Therapeutics, Inc.
    • Amplyx Pharmaceuticals, Inc.
    • DermaXon, LLC
    • Eisai Co., Ltd.
    • Immune Pharmaceuticals Inc.
    • Kineta, Inc.
    • Laboratorios Del Dr. Esteve S.A.
    • MAKScientific, LLC
    • Mertiva AB
    • Midatech Pharma US Inc.
    • Nemus Bioscience, Inc.
    • Novartis AG
    • Panacea Pharmaceuticals, Inc.
    • PeriphaGen, Inc.
    • PharmatrophiX, Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Virobay Inc.
  • Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amitriptyline + ketamine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-1710 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AXPN-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BR-297 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DX-0332 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E-2072 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E-52862 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EMA-401 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KRN-5500 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LM11A-31BHS - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NRX-2922 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PAN-811 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PGN-503 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Pain - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize CB1 and CB2 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPI-205 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VBY-036 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chemotherapy Induced Peripheral Neuropathy - Recent Pipeline Updates
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
  • Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
    • Featured News & Press Releases
      • Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA
      • Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program
      • Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA
      • Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation
      • Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2016
  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics, Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon, LLC, H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta, Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mertiva AB, H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience, Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Novartis AG, H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen, Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Chemotherapy Induced Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2016
  • Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2016
  • Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top